A Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant Acute Kidney Injury (AKI): Efficacy in Preventing Dialysis Dependent AKI

This is a prospective, double-blind, randomized, placebo-controlled study to assess the effects of suramin as a potential treatment option to prevent subjects with AKI from progressing to Kidney Disease Improving Global Outcomes (KDIGO) Stage III or dialysis dependent AKI.

Start Date13 Nov 2020

Sponsor / Collaborator

Rediscovery Life Sciences LLC

ChiCTR2000030029 / SuspendedEarly Phase 1IIT

A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)

Start Date20 Feb 2020

Sponsor / Collaborator

The First Affiliated Hospital, Zhejiang University School of Medicine

ChiCTR2100042004 / SuspendedEarly Phase 1IIT

A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)

Start Date19 Feb 2020

Sponsor / Collaborator-

100 Clinical Results associated with Suramin Sodium

100 Translational Medicine associated with Suramin Sodium

100 Patents (Medical) associated with Suramin Sodium

4,037

Literatures (Medical) associated with Suramin Sodium

01 Oct 2024·Molecular and Cellular Probes

SARS-CoV-2 replication and drug discovery

Review

Author: Bibi, Shaheen ; Zhang, Hongliang ; Wu, Songquan ; Khalid, Zunera ; Nazir, Farah ; Jin, Tengchuan ; John Kombe Kombe, Arnaud

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has killed millions of people and continues to wreak havoc across the globe. This sudden and deadly pandemic emphasizes the necessity for anti-viral drug development that can be rapidly administered to reduce morbidity, mortality, and virus propagation. Thus, lacking efficient anti-COVID-19 treatment, and especially given the lengthy drug development process as well as the critical death tool that has been associated with SARS-CoV-2 since its outbreak, drug repurposing (or repositioning) constitutes so far, the ideal and ready-to-go best approach in mitigating viral spread, containing the infection, and reducing the COVID-19-associated death rate. Indeed, based on the molecular similarity approach of SARS-CoV-2 with previous coronaviruses (CoVs), repurposed drugs have been reported to hamper SARS-CoV-2 replication. Therefore, understanding the inhibition mechanisms of viral replication by repurposed anti-viral drugs and chemicals known to block CoV and SARS-CoV-2 multiplication is crucial, and it opens the way for particular treatment options and COVID-19 therapeutics. In this review, we highlighted molecular basics underlying drug-repurposing strategies against SARS-CoV-2. Notably, we discussed inhibition mechanisms of viral replication, involving and including inhibition of SARS-CoV-2 proteases (3C-like protease, 3CL^pro or Papain-like protease, PL^pro) by protease inhibitors such as Carmofur, Ebselen, and GRL017, polymerases (RNA-dependent RNA-polymerase, RdRp) by drugs like Suramin, Remdesivir, or Favipiravir, and proteins/peptides inhibiting virus-cell fusion and host cell replication pathways, such as Disulfiram, GC376, and Molnupiravir. When applicable, comparisons with SARS-CoV inhibitors approved for clinical use were made to provide further insights to understand molecular basics in inhibiting SARS-CoV-2 replication and draw conclusions for future drug discovery research.

01 Oct 2024·The Lancet Infectious Diseases

New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine

Review

Author: Mesha, Tihitina ; Lindner, Andreas K ; Pasi, Christopher ; Villanueva, Gemma ; Barrett, Michael P ; Kadima Ebeja, Augustin ; Blumberg, Lucille ; Simarro, Pere P ; Chancey, Rebecca J ; Lejon, Veerle ; Priotto, Gerardo ; Bukachi, Salome A ; Probyn, Katrin ; Matemba, Lucas ; Franco, Jose R ; Akl, Elie A ; Edielu, Andrew ; Seixas, Jorge ; Mwanakasale, Victor ; Phiri, Tapunda

Human African trypanosomiasis is a neglected tropical disease that is usually fatal without treatment. WHO has revised its rhodesiense human African trypanosomiasis treatment guidelines on the basis of an independent systematic literature review and following the GRADE methodology. This Review reports on the decision-making process and summarises the new recommendations and their potential implications for health-care professionals and policy makers. Due to data scarcity, all recommendations are conditional and based on very low certainty of evidence. Fexinidazole replaces suramin and melarsoprol as the first-line therapy in individuals aged 6 years and older with a bodyweight of 20 kg or more. As fexinidazole is effective in both stages of rhodesiense human African trypanosomiasis, a lumbar puncture for staging is no longer required. In settings in which first-choice drugs are not readily available, immediate interim treatment with pentamidine is suggested. The introduction of oral fexinidazole represents an advancement in the management of rhodesiense human African trypanosomiasis considering the life-threatening adverse reactions individuals can have to melarsoprol. However, children below the age or weight limits remain ineligible for treatment with fexinidazole.

01 Oct 2024·Journal of the American Society of Nephrology

P2Y2R and Cyst Growth in Polycystic Kidney Disease

Article

Author: Leipziger, Jens ; Kraus, Andre ; Burzlaff, Nicolai ; Büttner-Herold, Maike ; Brötsch, Martin ; Schiffer, Mario ; Buchholz, Bjoern ; Skoczynski, Kathrin

Key Points

Polycystic kidney disease (PKD) is characterized by continuous cyst growth, which results in a decline in kidney function.

Deletion of P2Y2R and pharmacological antagonism of purinergic signaling significantly reduced cyst growth in an orthologous PKD mouse model.

P2Y2R was expressed in cysts of human PKD nephrectomies, which makes P2Y2R a reasonable target for treatment of PKD.

BackgroundAutosomal dominant polycystic kidney disease (ADPKD) is characterized by multiple bilateral kidney cysts that gradually enlarge, resulting in a decline in kidney function. Cyst growth is significantly driven by ATP-dependent chloride secretion mediated by the ion channel TMEM16A. This pathway is further augmented in advanced stages of the disease by hypoxia and activation of hypoxia-inducible factor (HIF)-1α. The mechanisms by which ATP leads to activation of TMEM16A and how HIF-1α contributes to cyst growth in vivo have remained elusive.MethodsMice with an inducible tubule-specific deletion of Pkd1 were compared with mice with an additional codeletion of the purinergic receptor P2y2r. Furthermore, animals were challenged by pharmacological activation of HIF-1α and Pkd1-deficient mice were treated with suramin, an antagonist of purinergic signaling. In addition, expression of P2Y2R, TMEM16A, and HIF-1α was analyzed in nephrectomy samples from 27 patients with ADPKD.ResultsGenetic deletion of P2y2r significantly inhibited cyst growth in vivo. In addition, aggravation of the polycystic phenotype mediated by pharmacological activation of HIF-1α was reduced by deletion of P2y2r. Application of suramin to pharmacologically inhibit purinergic signaling also suppressed cyst enlargement in vivo. Analysis of kidney samples from 27 patients with ADPKD revealed significant expression of P2Y2R at the luminal site of the cyst-lining epithelium.ConclusionsP2Y2R was significantly expressed in human and mouse polycystic kidneys. Deletion and antagonism of P2Y2R reduced cyst enlargement in an ADPKD mouse model.

News (Medical) associated with Suramin Sodium

15 May 2024

·www.biospace.com

PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101

TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq. Following receipt of notification from Nasdaq on April 30th, PaxMedica determined to appeal the decision and intends to maintain that the Hearings Panel did not consider sufficiently or appropriately crucial aspects of PaxMedica’s recent achievements and ongoing actions to regain compliance with all applicable requirements for continued listing. PaxMedica has retained Jacob Frenkel, Dickinson Wright, PLLC as its lead counsel in the appeal, working with the consulting firm that interacted previously with the Hearings Panel. Howard Weisman, CEO of PaxMedica, commented, "We are seeking a reevaluation of Nasdaq’s recent action based on new developments that underscore our ongoing progress and commitment to addressing global health challenges. Notably, following our announcements on the completion of registration lots of PAX-101 in mid-April, the Company just submitted a briefing book for an important FDA Type C meeting scheduled for June 27th, during which we will present key updates on our plans for NDA submission later this year. We believe this, as well as our financing plans, which we made known to the Hearings Panel, support persuasively our arguments to appeal and restore trading on Nasdaq." Recent milestones for PaxMedica include: April 11th: Completion of three pivotal registration/validation batches of PAX-101, an IV formulation of suramin, crucial for ongoing regulatory submissions. April 16th: Receipt of an urgent request from Malawi’s Ministry of Health for emergency access to suramin to address a looming humanitarian crisis due to the scarcity of treatment for TBr HAT, a fatal form of African Sleeping Sickness. April 23rd: Agreement to supply Malawi with PAX-101 from our stock, reinforcing our role in combating global health emergencies. May 10th: PaxMedica submits FDA Briefing Book for June 27, 2024, Type C meeting. Weisman stated "these actions not only demonstrate our operational effectiveness, but also our vital role in the global healthcare landscape. We are encouraged that the upcoming FDA meeting, and our continuous efforts to supply life-saving treatments, will result in favorable consideration by Nasdaq in our appeal." Nevertheless, PaxMedica acknowledges that it cannot predict the outcome of the appeal. Weisman added that “we are committed to advancing expeditiously our efforts to maximize shareholder opportunities and value and pursue approval of our solutions for neurological disorders.” PaxMedica remains resolute in its mission to develop and provide innovative treatments for neurological disorders, ensuring significant contributions to public health worldwide. For more information on PaxMedica’s ongoing initiatives and developments, please visit . About PaxMedica PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic disorders. Our comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as Autism Spectrum Disorder (ASD), as well as other critical areas within the neurology field. Additionally, we intend to provide the rest of the world with an additional, reliable source of suramin, the accepted standard of care for Stage 1, Trypanosoma Brucei Rhodesiense. We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on innovative ASD treatment solutions. Our ongoing research initiatives not only prioritize the needs of ASD patients, but also extend to exploring potential therapeutic applications for related conditions. To learn more about our transformative work, please visit Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at and by following PaxMedica on Twitter and LinkedIn. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue” or similar expressions. These forward-looking statements include our anticipated clinical program, the timing and success of our anticipated data announcements, pre-clinical and clinical trials and regulatory filings, and distribution and demand for our product candidates. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the Company’s product development and clinical trials, risk of insufficient capital resources, cash funding and cash burn, regulatory approvals and risks associated with intellectual property and infringement claims. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company’s “Risk Factors” section and other sections in its most recent Annual Report on Form 10-K, and subsequent quarterly and other filings with the U.S. Securities and Exchange Commission. Contacts PaxMedica, Inc. 303 S Broadway, Suite 125. Tarrytown, NY 10591 Media Contact media@paxmedica.com Investor Contact Scott McGowan InvestorBrandNetwork (IBN) Phone: 310.299.1717 ir@paxmedica.com SOURCE: PaxMedica, Inc.

10 May 2024

·www.sciencedaily.com

Metabolism of autism reveals developmental origins

Researchers have shed new light on the changes in metabolism that occur between birth and the presentation of autism spectrum disorder (ASD) later in childhood. The researchers discovered that a small number of biochemical pathways are responsible for the majority of these changes, which could help inform new early detection and prevention strategies for autism. Researchers at the University of California San Diego School of Medicine have shed new light on the changes in metabolism that occur between birth and the presentation of autism spectrum disorder (ASD) later in childhood. The researchers discovered that a small number of biochemical pathways are responsible for the majority of these changes, which could help inform new early detection and prevention strategies for autism. "At birth, the physical appearance and behavior of a child who will develop autism over the next few years are indistinguishable from that of a neurotypical child. Indeed, in most cases the fate of the child with regard to autism is not set at birth," said Robert Naviaux, M.D., Ph.D., professor in the Departments of Medicine, Pediatrics and Pathology at UC San Diego School of Medicine. "We're starting to learn about the governing dynamics that regulate the transition from risk to the actual appearance of the first symptoms of ASD. Early diagnosis opens the possibility of early intervention and optimal outcomes." ASD is a developmental disorder characterized by difficulties in socializing and communication, as well as repetitive and/or restrictive behaviors. For the majority of people with ASD, the condition is a significant disability, with only 10-20 percent of children diagnosed before 5 years of age able to live independently as adults. While autism is known to have strong genetic risk factors, there are also environmental risk factors that play a role in the development and severity of ASD. Naviaux and other researchers are discovering that the development of autism is governed by the real-time interaction of these varied factors. By studying the developmental biology of metabolism and how it differs in autism, new insights are emerging in ASD and other complex developmental disorders. "Behavior and metabolism are linked -- you cannot separate them," added Naviaux. To learn more about the early metabolic changes that occur in children with autism, researchers studied two cohorts of children. One cohort consisted of newborn children, in whom autism can't be detected. The second cohort consisted of 5-year-old children, some of whom had been diagnosed with autism. When comparing the metabolic profiles of children in the cohort who were eventually diagnosed with autism to those who developed neurotypically, they found striking differences. Of the 50 different biochemical pathways the researchers investigated, just 14 were responsible for 80 percent of the metabolic impact of autism. The pathways that were most changed are related to the cell danger response, a natural and universal cellular reaction to injury or metabolic stress. The body has biochemical safeguards in place that can shut down the cell danger response once the threat has passed, and Naviaux hypothesizes that autism occurs when these safeguards fail to develop normally. The result is heightened sensitivity to environmental stimuli, and this effect contributes to sensory sensitivities and other symptoms associated with autism. "Metabolism is the language that the brain, gut and immune system use to communicate, and autism occurs when the communication between these systems is changed," added Naviaux. The cell danger response is primarily regulated by adenosine triphosphate (ATP) the body's chemical energy currency. While these ATP-signaling pathways do not develop normally in autism, they may be partially restorable with existing pharmaceutical drugs. In 2017, Naviaux and his team completed early clinical testing for suramin, the only drug approved in humans that can target ATP signaling and which is normally used to treat African sleeping sickness. Now, the researchers hope that by revealing the specific ATP-related pathways that are altered in autism, their work will help scientists develop more drugs that target these pathways to manage the symptoms of ASD. "Suramin is just one drug that targets the cell danger response," he said. "Now that we're closely interrogating how metabolism changes in ASD, we could be at the beginning of a drug renaissance that will create new options for treatment that never existed before." Co-authors on the study include: Sai Sachin Lingampelly, Jane C. Naviaux, Jonathan M. Monk, Kefeng Li and Lin Wang at UC San Diego School of Medicine and Luke S. Heuer, Lori Haapanen, Chelsea A. Kelland and Judy Van de Water at University of California Davis This work was funded, in part, by Autism Speaks (grant 7274), the National Center for Research Resources (grant UL1TR001442), and through various philanthropic gifts.

Drug Approval

07 May 2024

·www.globenewswire.com

PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy

TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders. Howard Weisman, CEO of PaxMedica, affirmed, "Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for anti-purinergic therapies to address the core symptoms of autism spectrum disorder (ASD)." The company is preparing to file a New Drug Application (NDA) with the FDA for the use of suramin in treating Human African Trypanosomiasis (HAT) as it has previously reported. Suramin has been recognized for nearly a century as a standard treatment for HAT in East Africa. In April 2024, PaxMedica responded to an urgent request from Malawi for an emergency release of suramin, underscoring the company’s commitment to addressing global health crises. "We are not just continuing; we are intensifying our efforts to achieve significant milestones for these programs by the end of this year," Weisman added. "We are on track to submit an NDA for PAX-101, and potentially secure an FDA Priority Review Voucher if approved." This proactive approach illustrates PaxMedica's dedication to advancing healthcare solutions globally. About PaxMedica PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic disorders. Our comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as Autism Spectrum Disorder (ASD), as well as other critical areas within the neurology field. Additionally, we intend to provide the rest of the world with an additional, reliable source of suramin, the accepted standard of care for Stage 1, Trypanosoma Brucei Rhodesiense. We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on innovative ASD treatment solutions. Our ongoing research initiatives not only prioritize the needs of ASD patients, but also extend to exploring potential therapeutic applications for related conditions. To learn more about our transformative work, please visit www.paxmedica.com. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.paxmedica.com/email-alerts and by following PaxMedica on Twitter and LinkedIn. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue” or similar expressions. These forward-looking statements include our anticipated clinical program, the timing and success of our anticipated data announcements, pre-clinical and clinical trials and regulatory filings, and distribution and demand for our product candidates. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the Company’s product development and clinical trials, risk of insufficient capital resources, cash funding and cash burn, regulatory approvals and risks associated with intellectual property and infringement claims. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company’s “Risk Factors” section and other sections in its most recent Annual Report on Form 10-K, and subsequent quarterly and other filings with the U.S. Securities and Exchange Commission. Contacts PaxMedica, Inc. 303 S Broadway, Suite 125. Tarrytown, NY 10591 www.paxmedica.com Media Contact media@paxmedica.com Investor Contact Scott McGowan InvestorBrandNetwork (IBN) Phone: 310.299.1717 ir@paxmedica.com www.paxmedica.com/investors SOURCE: PaxMedica, Inc.

NDAPriority Review

100 Deals associated with Suramin Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
-	Suramin Sodium	P01CX02	DB04786

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Onchocerciasis	DE	Bayer AG	01 Jan 1940
Trypanosomiasis, African	DE	Bayer AG	01 Jan 1940

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Trypanosomiasis, African	Phase 3	-	PaxMedica, Inc.	-
Acute Kidney Injury	Phase 2	US	Rediscovery Life Sciences LLC	13 Nov 2020
Autism Spectrum Disorder	Phase 2	-	PaxMedica, Inc.	-
Post Acute COVID 19 Syndrome	Phase 1	ZA	PaxMedica, Inc.	07 Jan 2022
Fatigue Syndrome, Chronic	Preclinical	US	PaxMedica, Inc.	26 Nov 2022
Fragile X Tremor Ataxia Syndrome	Preclinical	-	PaxMedica, Inc.	-
Hand, Foot and Mouth Disease	Discovery	CN	Guangdong Kangda Pharmaceutical Co. Ltd.	20 Dec 2018
Hand, Foot and Mouth Disease	Discovery	CN	Jiangsu Kingsley Pharmaceutical Co., Ltd.	20 Dec 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01671332 (CTgov)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	80	Docetaxel (Docetaxel)	mfawsugqbp(mebpkaphwb) = dkspsparic ptlutnwcvd (lbrtprueun, eqljmxvvuc - kiyrxwpmlq) View more	-	12 May 2020
				Suramin+Docetaxel (Docetaxel Plus Suramin)	mfawsugqbp(mebpkaphwb) = fysxjfbgen ptlutnwcvd (lbrtprueun, zevsxjhclb - wtggsrkeef) View more
NCT00054028 (CTgov)	Phase 1/2	Breast cancer recurrent \| Metastatic breast cancer \| Advanced breast cancer	31	pharmacological study+suramin+paclitaxel	ghoujgljvg(pztljsjgos) = eyraqofrlj gdxhdrzrif (qyezldcive, jdbgqldrud - lxcylevexm)	-	17 Mar 2015
NCT01038752 (CTgov)	Phase 2	Non-Small Cell Lung Cancer	14	Suramin Drug:Docetaxel Drug: Carboplatin (Suramin)	yjmtivocdy(qmvryfbwsf) = bxxtfcrsfo hqvbmllqzv (jodxddbsxg, dlleiighca - kkwkhuqand) View more	-	21 Oct 2014
				Placebo Drug: Docetaxel Drug: Carboplatin (Standard of Care)	yjmtivocdy(qmvryfbwsf) = shxdrktrxt hqvbmllqzv (jodxddbsxg, rjnmtxqomq - hltgvlydap) View more
ARVO2011	Not Applicable	Optic Nerve Injuries	-	Brilliant Blue G	kkyrborjvx(nuweebhzqp) = jikiduvpgq cbogwqkfak (xujctzsfpw ) View more	-	01 Apr 2011
				Vehicle (0.9% NaCl)	(qbhcxvyjjx) = eqvdghbmsn jvqlgfoktv (yrmcpgjhwu )
ARVO2006	Not Applicable	Retinal Neovascularization P2X 2 \| P2Y 2	-	Suramin	qilaggycmt(hwclgsgjcr) = kjngcsofas kagjmwihsd (nnpbfyqcoi )	Positive	01 May 2006
				Suramin	qilaggycmt(hwclgsgjcr) = btooyevwgz kagjmwihsd (nnpbfyqcoi )
ASCO2004	Phase 2	Non-Small Cell Lung Cancer	54	Low dose suramin	ptfonlnvnu(gzdouaoidr) = phxvlrcgxq urvwrezahh (bwjsuomyii, 22–54)	-	15 Jul 2004
NCT00004073 (NABTT CNS Consortium, Pubmed \| Neuro Oncol)	Phase 2	Glioblastoma	55	Suramin	ykotolomnp(bpsjfmkwfs) = mzgfmcntkx rqicjomhoz (tsvutvzseb )	Negative	01 Jan 2004
NCT00002723 (Intergroup 0159, Cancer and Leukemia Group B 9480, Pubmed \| J Urol)	Phase 3	Advanced Prostate Carcinoma	390	Low-dose suramin	(nqhpjkxbsn) = fjkpfklgph nqblhpmmon (mnmktzfxfx ) View more	Negative	15 Aug 2002
				Intermediate-dose suramin	(nqhpjkxbsn) = mxsdyswdtp nqblhpmmon (mnmktzfxfx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis